{
    "nct_id": "NCT06586515",
    "official_title": "A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
    "inclusion_criteria": "* Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA\n* Have an ECOG performance status of ≤ 1\n* Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease\n* Participants with asymptomatic or treated CNS disease may be eligible.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have known active CNS metastases and/or carcinomatous meningitis.\n* Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.\n* Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.\n* Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.\n* Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).\n* Have other active malignancy unless in remission with life expectancy greater than (>) 2 years.",
    "miscellaneous_criteria": ""
}